Children’s hospitals depend on a reliable and safe drug and supply chain to provide life-saving treatments to their pediatric patients.

Children’s health groups are asking HHS and the DEA to convene stakeholders to identify actionable solutions about ongoing stimulant medication shortages.

The 340B program supports children’s hospitals in their mission to serve low-income and underinsured children regardless of their insurance status.

CHA submitted comments on a drug shortages white paper to highlight pediatric health care needs.

Cell and gene therapies have the potential to address unmet pediatric medical needs, reduce the need for costly chronic care, and help address health disparities.

CHA submitted a comment letter to the Energy and Commerce Committee to highlight pediatric needs when addressing drug shortages.

CHA submitted a response to the bicameral drug shortages request for information (RFI) to highlight pediatric health care needs.

The 340B program supports children’s hospitals in their mission to serve low-income and underinsured children regardless of their insurance status.

Children’s Hospital Association sent a comment letter to the Centers for Medicare and Medicaid Services on the 340B remedy proposed rule.